You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

387 Results
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative, Curative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Advanced or Recurrent Endometrial Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
trastuzumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - In Combination with Platinum Doublet Chemotherapy for First Line Metastatic or Recurrent Non-Small Cell Lung Cancer
New Drug Funding Program
    Nivolumab plus Ipilimumab - In Combination with Platinum Doublet Chemotherapy for First Line Metastatic or Recurrent Non-Small Cell Lung Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab,
ipilimumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    venetoclax - In Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia, based on criteria
Exceptional Access Program
    venetoclax - In Combination with Rituximab - Relapsed Chronic Lymphocytic Leukemia, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
venetoclax
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Guidelines and Advice
Status: Current
Version: 2
Dec 2024
Regimen
Cancer Type:
Gastrointestinal, 
Mesothelioma (Peritoneal)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
pemetrexed,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet
Jan 2024
Drug
Other Name(s): Piqray®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2024
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Drugs Used:
nivolumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Blinatumomab - Minimal Residual Disease (MRD)-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
blinatumomab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Guidelines and Advice
Status: Current
Version: 3.1
Oct 2024
Regimen
Cancer Type:
Breast, 
Central Nervous System, 
Endocrine, 
Adrenal, 
Neuroendocrine, 
Pancreatic Neuroendocrine, 
Parathyroid, 
Thymoma, 
Thyroid, 
Gastrointestinal, 
Anus, 
Colorectal, 
Esophagus, 
Gastric / Stomach, 
Gastrointestinal Stromal Tumours, 
Hepatobiliary / Liver / Bile Duct, 
Mesothelioma (Peritoneal), 
Neuroendocrine (GI), 
Pancreas, 
Rectal, 
Small bowel and appendix, 
Genitourinary, 
Bladder / Urothelial, 
Penile, 
Prostate, 
Renal cell / Kidney, 
Testis, 
Gynecologic, 
Cervix, 
Endometrial, 
Germ Cell, 
Gestational Trophoblastic Disease, 
Ovary, 
Uterine Sarcoma, 
Vagina, 
Vulva, 
Head and Neck, 
Larynx, 
Nasopharynx, 
Oral, 
Paranasal Sinus, 
Pharynx, 
Salivary Gland, 
Squamous Cell, 
Kaposi's Sarcoma, 
Lung, 
Mesothelioma (Pleural), 
Neuroendocrine (Lung), 
Non-Small Cell, 
Small Cell, 
Sarcoma, 
Desmoid Tumour, 
Ewing's, 
Ewing's and Soft Tissue, 
GIST, 
Giant Cell Tumour, 
Kaposi's Sarcoma, 
Osteogenic / Bone, 
Soft Tissue, 
Uterine, 
Wilm's Tumour, 
Skin, 
Basal Cell, 
Melanoma, 
Merkel Cell, 
Squamous Cell, 
Unknown Primary
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    larotrectinib - For the treatment of unresectable locally advanced, or metastatic solid tumours with neurotrophic tyrosine receptor kinase (NTRK) gene fusion, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
larotrectinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    zanubrutinib - For the treatment of relapsed or refractory Waldenström Macroglobulinemia, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
zanubrutinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024
Regimen
Cancer Type:
Gynecologic, 
Vulva
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet (Every 3 weeks)
Jan 2024

Pages